Journal Mobile Options
Table of Contents
Vol. 53, No. 4, 2005
Issue release date: July 2005
Eur Neurol 2005;53:197–202
(DOI:10.1159/000086479)

Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment

Brooks D.J. · Agid Y. · Eggert K. · Widner H. · Østergaard K. · Holopainen A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo® (levodopa, carbidopa and entacapone) in patients with Parkinson’s disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess®/Comtan®). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCI to either an equivalent dose of Stalevo or levodopa/DDCI plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson’s Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCI plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCI and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCI preparations.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):S1–S88.
  2. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C: Treatment interventions for Parkinson’s disease: an evidence-based assessment. Lancet 2002;359:1589–1598.
  3. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448–458.
  4. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931–1938.
  5. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–1491.
  6. Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC: Clinical experience with controlled-release carbidopa/levodopa in Parkinson’s disease. Neurology 1993;43:677–681.
  7. Koller WC, Pahwa R: Treating motor fluctuations with controlled-release levodopa preparations. Neurology 1994;44(suppl 6):S23–S28.
  8. Koller WC, Hutton JT, Tolosa E, Capilldeo R: Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53:1012–1019.
  9. Myllyla VV, Sotaniemi KA, Illi A, Suominen K, Keranen TI: Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson’s disease. Eur J Clin Pharmacol 1993;45:419–423.
  10. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913–919.
  11. Ruottinen HM, Rinne UK: A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol 1996;19:283–296.
  12. Poewe W: The role of COMT inhibition in the treatment of Parkinson’s disease. Neurology 2004;62(suppl 1):S31–S38.
  13. Parkinson Study Group: Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann Neurol 1997;42:747–755.
  14. Rinne UK, Larsen JP, Siden A, Worm-Petersen J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309–1314.
  15. Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M, FILOMEN Study Group: Twelve-month safety of entacapone in patients with Parkinson’s disease. Eur J Neurol 2001;8:53–60.
  16. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group: Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245–255.
  17. Brooks DJ, Sagar H: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: A randomised, placebo-controlled, double-blind, six-month study. J Neurol Neurosurg Psychiatry 2003;74:1071–1079.
  18. Zhang Z, Li H, Luo Y, Jiang Y, Chen S, Chen H, Sun B, Wen H, Wang J, Weng Z, Wang X, et al: A randomized, placebo-controlled, double-blind, parallel-group trial of entacapone in patients with fluctuating Parkinson’s disease. Clin J Neurol 2003;36:406–410.
  19. Gershanik O, Emre M, Bernhard G, Sauer D: Efficacy and safety of levodopa with entacapone in Parkinson’s disease patients suboptimally controlled with levodopa alone, in daily clinical practice: An international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:963–971.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50